Therapix Biosciences Ltd., a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform THX-110, announced topline results from its investigator-initiated Phase IIa study at Yale University, suggesting that THX-110—a combination of dronabinol (∆-9-tetrahydracannabinol) and palmitoylethanolamide (PEA)—significantly improved symptoms over time in adult Subjects with Tourette syndrome. “The successful completion of…